Price information and purchasing methods of ADAMTS13 recombinant protease (trade name: Apadase α, English: Adzynma)

ADAMTS13 recombinant protease , also known as apadaseα (Adzynma), is a carefully developed human recombinant drug. Its core component is "disintegrin and metalloprotease with thrombospondin motif 13" ADAMTS13 (rADAMTS13). The advent of this drug brings new treatment hope to adults and children with congenital thrombotic thrombocytopenic purpura (cTTP). It can effectively improve patients’ symptoms and improve their quality of life through preventive or on-demand enzyme replacement therapy (ERT).

In the process of drug development and approval,Adzynma has won recognition from many parties with its unique efficacy and safety. The U.S. FDA not only granted it Orphan Drug Designation (ODD) in recognition of its outstanding contribution in the treatment of the rare disease TTP (including acquired idiopathic and secondary forms), but also opened a fast track for it and specifically granted it Rare Pediatric Disease Designation. This series of honors and recognitions undoubtedly laid a solid foundation for Adzynma’s widespread application. It is worth mentioning that Takeda was awarded the rare pediatric disease certificate by the U.S. FDA due to the outstanding performance of Adzynma, further demonstrating the unique value of this drug in the field of pediatric treatment.

In addition,Adzynma’s excellent efficacy and safety have also been widely recognized by the international community. The European Medicines Agency (EMA) and the Japanese Ministry of Health, Labor and Welfare (MHLW) also granted it ODD for the treatment of TTP. This cross-border recognition not only proves Adzynma's broad application prospects around the world, but also injects strong impetus into its future research and development and promotion.

ADAMTS13 recombinant protease is not currently on the market in the country. However, China has listed it as a priority review project and actively promoted its domestic listing process. It is believed that in the near future, patients will be able to purchase this drug in the country. If patients are interested in this drug and want to know more, they can consult a medical consultant.

Reference link:https://www.drugs.com/adzynma.html